These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24599932)
1. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932 [TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW Clin Cancer Res; 2015 Nov; 21(22):5082-5091. PubMed ID: 26138065 [TBL] [Abstract][Full Text] [Related]
3. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768 [TBL] [Abstract][Full Text] [Related]
4. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731 [TBL] [Abstract][Full Text] [Related]
5. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response. Guo Q; Abraham JE; Caldas C; Earl HM; Pharoah PP; Clin Cancer Res; 2015 Jul; 21(13):3094. PubMed ID: 26133777 [No Abstract] [Full Text] [Related]
6. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter. Apellániz-Ruiz M; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Sereno M; García-Donás J; Åvall-Lundqvist E; Gréen H; Brøsen K; Bergmann TK; Rodríguez-Antona C Clin Cancer Res; 2015 Jul; 21(13):3092-3. PubMed ID: 26133776 [No Abstract] [Full Text] [Related]
7. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. Tanabe Y; Shiraishi S; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y; Shimizu C BMC Cancer; 2020 Apr; 20(1):325. PubMed ID: 32295642 [TBL] [Abstract][Full Text] [Related]
8. SNPs and taxane toxicity in breast cancer patients. Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407 [TBL] [Abstract][Full Text] [Related]
9. Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2-functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer. Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S Support Care Cancer; 2023 Feb; 31(3):178. PubMed ID: 36809570 [TBL] [Abstract][Full Text] [Related]
10. Polymorphism of Yang Y; Jia J; Sun Z; Liu C; Li Z; Xiao Y; Yu J; Du F; Shi Y; Sun J; Shui J; Zhang X Future Oncol; 2021 Jun; 17(18):2351-2363. PubMed ID: 33709789 [TBL] [Abstract][Full Text] [Related]
11. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123 [TBL] [Abstract][Full Text] [Related]
14. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S Support Care Cancer; 2023 Jan; 31(2):139. PubMed ID: 36707490 [TBL] [Abstract][Full Text] [Related]
15. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211 [TBL] [Abstract][Full Text] [Related]
17. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors. Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889 [TBL] [Abstract][Full Text] [Related]
18. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. Su Y; Huang J; Wang S; Unger JM; Arias-Fuenzalida J; Shi Y; Li J; Gao Y; Shi W; Wang X; Peng R; Xu F; An X; Xue C; Xia W; Hong R; Zhong Y; Lin Y; Huang H; Zhang A; Zhang L; Cai L; Zhang J; Yuan Z J Natl Cancer Inst; 2020 Jan; 112(1):55-62. PubMed ID: 31093677 [TBL] [Abstract][Full Text] [Related]